FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

Novartis announced today that the US Food and Drug Administration (FDA) approved Menveo® (Meningococcal Group A, C, W-135 and Y conjugate vaccine) for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis (N. meningitidis) in infants and toddlers from 2 months of age[1]. With this expanded indication, pediatricians in the US can now offer a single vaccine for the protection of infants, children and adolescents against four of the five most common serogroups that cause meningococcal disease[1],[5].

“Each year, more children in the US die or are left with permanent disability from meningococcal disease than from two other diseases combined that we routinely vaccinate infants against – rotavirus and varicella,” said Dr. Steve Black, Center for Global Health, University of Cincinnati Children’s Hospital. “With the expanded indication for this MCV4 vaccine, we now have the opportunity to help protect our infants against four strains of meningococcal disease earlier, when they are most vulnerable.”

Infants younger than 7 months old are the most vulnerable age group to meningococcal disease in the US. In their first year of life, infants are more than seven times more likely to contract the disease than 14 to 24 year olds[4]. Of the infants who contract the disease, more than 10 percent will die from it and of those who do survive, approximately one in every five will suffer permanent, devastating side effects, including amputations, hearing loss, paralysis and brain damage[3],[6].

“Despite recommendations for routine immunization of adolescents, college students living in dormitories and certain infants in the US, meningococcal disease continues to kill and maim,” said Andrin Oswald, Head of Novartis Vaccines and Diagnostics. “With this approval for the expanded use of Menveo, we hope that health authorities will deploy this vaccine to further reduce the burden of this devastating disease in the US.”

This FDA approval was based on data from three randomized multicenter studies involving more than 8,700 infants, conducted in Australia, Canada, Latin America, Taiwan and the US. The studies demonstrated that Menveo generated a robust protective immune response and was generally well tolerated when administered with other routine pediatric vaccines[1].

About Menveo

Menveo is a quadrivalent conjugate vaccine for use to protect against invasive disease caused by four groups of the bacterium Neisseria meningitidis (A, C, Y and W-135)[1]. As of July 2013, Menveo is registered in more than 50 countries for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y[1]. Studies are ongoing in infants, toddlers, adolescents and adults.

Menveo has been available for use in adolescents and adults (11 to 55 years of age) since February 2010 and in children (2 to 10 years of age) since January 2011[1],[7].

For more information about Menveo, visit www.menveo.com.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of Menveo, any component of this vaccine, or any other CRM197, diphtheria toxoid or meningococcal-containing vaccine is a contraindication to administration of Menveo. Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of Menveo.

Syncope, sometimes resulting in falling injury associated with seizure-like movements has been reported following vaccination with Menveo. Vaccinees should be observed for at least 15 minutes after vaccine administration to prevent and manage syncopal reactions.

Safety and effectiveness of Menveo have not been evaluated in immunocompromised persons. If Menveo is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained.

Guillain-Barré Syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer Menveo to subjects with a known history of GBS should take into account the potential benefits and risks.

Apnea following intramuscular vaccination has been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including Menveo, to an infant born prematurely should be based on consideration of the individual infant’s medical status, and the potential benefits and possible risks of vaccination.

In clinical trials, common solicited adverse reactions with Menveo among children initiating vaccination at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting and diarrhea. Common solicited adverse reactions among children initiating vaccination at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits and diarrhea. Common solicited adverse reactions among children 2 years through 10 years of age were injection site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults were pain at the injection site, headache, myalgia, malaise and nausea. Some events were severe. Safety has not been established in pregnant women. Vaccination with Menveo may not protect all individuals.

Before administering Menveo, please see full Prescribing Information.

References

1. Menveo Prescribing Information. Revised August 13, 2013. To be confirmed.
2. Centers for Disease Control and Prevention. Vaccine Information Statements (VIS). Meningococcal VIS. October 2011 Update. Available at: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html. Accessed July 2013.
3. Poland, GA. Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines. Clinical Infectious Diseases 2010:50 (Suppl 2):S45-S53.
4. Cohn, A. et al. Changes in Neisseria meningitides Disease Epidemiology in the United States, 1998-2007: Implications for Prevention of Meningococcal Disease. Clinical Infectious Diseases 2010:50.
5. Centers for Disease Control and Prevention. Meningococcal Disease: Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book: Course Textbook). 12 Edition, 2nd Printing. May 2012 update. Available at: http://www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed: July 2013.
6. World Health Organization. Meningococcal meningitis. Fact sheet #141. November 2012. Available at: http://www.who.int/mediacentre/factsheets/fs141/en/. Accessed July 2013.
7. Novartis Press Release. FDA requests additional data on Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for expanded use in infants and toddlers. Available at: http://www.novartis.com/newsroom/media-releases/en/2012/1584870.shtml. Accessed July 2013.